Esomeprazole sodium
CAS No. 161796-78-7
Esomeprazole sodium ( S)-Omeprazole sodium )
产品货号. M12368 CAS No. 161796-78-7
一种质子泵抑制剂,通过抑制壁细胞中的 H+/K+-ATP 酶来减少胃酸分泌。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥341 | 有现货 |
|
| 10MG | ¥556 | 有现货 |
|
| 50MG | ¥1133 | 有现货 |
|
| 100MG | ¥1418 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Esomeprazole sodium
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种质子泵抑制剂,通过抑制壁细胞中的 H+/K+-ATP 酶来减少胃酸分泌。
-
产品描述A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells; the (S)-(?)-enantiomer of omeprazole for treatment of dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease.Ulcer Approved(In Vitro):Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.(In Vivo):Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.
-
体外实验Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification. Cell Viability AssayCell Line:MDA-MB-468 cellsConcentration:25 μM, 50 μM, 75 μM, 100 μM Incubation Time:20 hours Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
-
体内实验Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis. Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury Dosage:30 mg/kg, 300 mg/kg Administration:Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
-
同义词S)-Omeprazole sodium
-
通路Membrane Transporter/Ion Channel
-
靶点Proton Pump
-
受体H+/K+-ATPase
-
研究领域Other Indications
-
适应症Ulcer
化学信息
-
CAS Number161796-78-7
-
分子量367.3979
-
分子式C17H18N3NaO3S
-
纯度>98% (HPLC)
-
溶解度10 mM in H2O
-
SMILESCC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+]
-
化学全称1H-Benzimidazole, 6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
WY-47766
WY-47766(OST-766) 是一种质子泵抑制剂。
-
Tegoprazan
一种新型强效、高选择性、竞争性和口服活性的胃 H+/K+-ATP 酶抑制剂,体外猪、犬和人 H+/K+-ATP 酶的 IC50 范围为 0.29-0.52 uM。
-
Bafilomycin A1
Bafilomycin A1 是一种从链霉菌属物种中分离出来的大环内酯类抗生素,也是液泡 V-ATP 酶的抑制剂。
021-51111890
购物车()
sales@molnova.cn

